Now we just might be crazy, but we do believe in those pesky little things called facts. And the facts pretty much say two things when it comes to our chardonnay guzzling friends and diabetes devices – that Sanofi has no business being in the device arena and they are THE worst company to partner with. Again not to belabor a point but here are just some of what we are talking about-
April 2010 Sanofi and AgaMatrix –
“AgaMatrix, Inc. and sanofi-aventis (EURONEXT: SAN andNYSE: SNY) today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix’s WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices. Sanofi-aventis’ insulin and device portfolio include Lantus®, a basal insulin that is the number one insulin prescribed worldwide, and Apidra®, a leading fast-acting insulin, plus its easy-to-use delivery pens SoloSTAR® and ClikSTAR®.”
June 2014 Sanofi and Medtronic –
“Sanofi (EURONEXT: SAN and NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) today announced that they have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world. The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help people with diabetes better manage their condition.”
April 2018 – Sanofi and Common Sensing –
“Common Sensing (http://www.common-sensing.com), an evidence-based, data-driven injectable-medicine healthcare company, today announced the close of a $6.6 million USD Series A financing. The round was led by Waterline Ventures. New World Health, Royal Philips (NYSE: PHG; AEX: PHIA), Qualcomm Ventures (the investment arm of Qualcomm Incorporated), Sanofi Ventures, and Haselmeier joined the round as well. The funds will be used to accelerate Common Sensing’s manufacturing and commercial operations for Gocap™, an IP-protected dose monitoring solution enabling patients and providers to better utilize injectable medicine, including insulin, fertility medications, growth hormones, and others.”
July 2019 – Sanofi and BIOCORP
“ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces that they have entered into an exclusive negotiation with SANOFI, a worldwide leader within the pharmaceutical industry, aimed at introducing their Mallya connected device into SANOFI’s integrated diabetes care platform.”
Ok it’s too early to call the BIOCORP deal a failure but given their track record we’re fairly confident this latest device partnership will fear no better than the others that came and went before. As the FACTS make clear when it comes to diabetes devices Sanofi has the reverse Midas touch. As Albert Einstein once said the definition of insanity is performing the exact same behavior over and over yet expecting a different result.
Yet devices aren’t the only area where the company has demonstrated extraordinary ineptitude just ask the folks at Lexicon or our friends at Google. It really doesn’t matter Sanofi touches in diabetes for whatever they touch it goes to hell in a handbasket. Now to be fair most large pharmaceutical companies haven’t fared much better than Sanofi when it comes to devices but Sanofi’s dismal track record stands above the rest.
What’s truly astonishing here is the company with this proven track record for failure keeps repeating the same mistakes. That no one is held accountable and this cycle of futility continues unabated.
Listen we don’t blame companies for partnering with Sanofi, frankly, most need the money. Or in the case of Medtronic and Google believe their expertise will overcome Sanofi’s stupidity.
Yet the facts are it takes two to tango and Sanofi is terrible dance partner.